Evaluation on efficacy and safety of a combination therapy of rituximab with bendamustin in the patients with relapsed or resistnat low grade B-cell non-Hodgkin lymphoma
Phase 4
- Conditions
- patients with relapsed or resistant low grade B-cell non-Hodgkin lymphoma
- Registration Number
- JPRN-UMIN000008638
- Lead Sponsor
- Hiroshima University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 26
Inclusion Criteria
Not provided
Exclusion Criteria
1) infected definitely 2) critical complication (liver failure or renal failure) 3) critical complication of heart disease 4) critical complication of bowel disease 5) positive for HBsAb, HCVAb, or HIVAb 6) critical hemostatic disease 7) involved in CNS 8) febrile >38C (except for tumor fever) 9) critical complication of respiratory disease 10) concomittent presence of another malignancy 11) AIHA 12) allergy of bendamustine 13) pregnant or breast-feeding 14) allergy of rituximab 15) uncontrol of contraception 16) not eligible for this study
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method ORR
- Secondary Outcome Measures
Name Time Method CR rate PFS adverse effect and data on laboratory findings